Core Viewpoint - A total of 34 companies will have 1.407 billion shares released from restrictions next week, with a total market value of 24.733 billion yuan, representing an increase of 742 million yuan compared to the previous week [1] Group 1: Upcoming Unlocks - The peak unlock day is on Monday, November 10, with an unlock scale of 12.563 billion yuan, accounting for 50.79% of the total for the week [1] - The top three companies by unlock market value are Youyan Silicon (99.91 billion yuan), XinNuoWei (49.48 billion yuan), and Juxing Technology (32.97 billion yuan) [1] Group 2: Detailed Unlock List - Youyan Silicon: Unlock date on November 10, market value of 99.91 billion yuan, with 74,005.54 thousand shares, accounting for 59.32% of total shares [2] - XinNuoWei: Unlock date on November 14, market value of 49.48 billion yuan, with 15,752.05 thousand shares, accounting for 11.21% of total shares [4] - Juxing Technology: Unlock date on November 11, market value of 32.97 billion yuan, with 11,826.6 thousand shares, accounting for 76.22% of total shares [3]

Core Viewpoint - A total of 34 companies will have their restricted shares unlocked between November 10 and 14, with a combined market value exceeding 24.7 billion yuan based on the latest closing prices [2] Group 1: Unlocking Market Value - The peak unlocking date is November 10, with the highest market values for unlocked shares being: Youyan Silicon (688432.SH) at 9.991 billion yuan, Xinnowei (300765.SZ) at 4.948 billion yuan, and Juxing Technology (920111.BJ) at 3.297 billion yuan [2] Group 2: Unlocking Share Volume - The top three companies by the number of unlocked shares are: Youyan Silicon with 740 million shares, Xinnowei with 158 million shares, and Beibu Gulf Port (000582.SZ) with 156 million shares [2]

Economic Data Release - The National Bureau of Statistics will release October economic data on November 14, including industrial added value, fixed asset investment, and retail sales [2] - Financial data for October, such as M2, new loans, and social financing, is also expected to be released next week [3] Industry Conferences - A series of industry conferences will take place in November, including the 2025 China Robot Industry Development Conference from November 10 to 12, and the 12th China (Suzhou) Battery New Energy Industry International Summit Forum from November 11 to 13 [4] - Other notable events include the 2025 World Power Battery Conference, the 2025 Fourth China Nuclear Energy High-Quality Development Conference, and the 2025 6G Development Conference [4] Fuel Price Adjustment - A new round of domestic fuel price adjustments will begin on November 10 at 24:00, with an expected increase of 130 yuan per ton for gasoline and diesel based on the average crude oil price of 62.52 USD per barrel [5] Stock Unlocking - Over 24.7 billion yuan worth of restricted shares will be unlocked next week, with a peak unlocking date on November 10 [6] - The top three companies by unlocking market value are Youyan Silicon (99.91 million yuan), Xin Nuowei (49.48 million yuan), and Juxing Technology (32.97 million yuan) [6] New Stock Opportunities - Two new stocks will be issued next week: Nant Technology on November 11 and Hai'an Group on November 14 [9]

Core Viewpoint - New Nuo Wei's stock price has experienced significant fluctuations, with a year-to-date increase of 19.08% but a recent decline of 35.44% over the past 60 days, indicating potential volatility in the market [1]. Financial Performance - For the period from January to September 2025, New Nuo Wei reported a revenue of 1.593 billion yuan, reflecting a year-on-year growth of 7.71%. However, the net profit attributable to shareholders was a loss of 24.05 million yuan, a decrease of 117.26% compared to the previous year [2]. - Cumulatively, since its A-share listing, New Nuo Wei has distributed a total of 651 million yuan in dividends, with 500 million yuan distributed over the past three years [3]. Shareholder Structure - As of October 31, 2025, the number of shareholders for New Nuo Wei increased by 32.87% to 21,800, while the average number of circulating shares per person decreased by 24.74% to 57,116 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 17.7822 million shares, a decrease of 3.2169 million shares from the previous period [3].

Core Viewpoint - The company announced the acquisition of a 29% stake in its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., increasing its ownership from 51% to 80% through a cash transaction valued at 1.1 billion yuan [2]. Group 1 - The board of directors and the supervisory board held meetings on September 30, 2025, to approve the acquisition proposal [2]. - The extraordinary general meeting of shareholders is scheduled for October 16, 2025, to further discuss the transaction [2]. - The transaction has been completed with the necessary registration changes filed with the relevant administrative authority [2].

证券代码：300765 证券简称：新诺威 公告编号：2025-085 石药创新制药股份有限公司 关于收购控股子公司石药集团巨石生物制药有限公司 部分少数股权交易进展暨完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）于 2025 年 9 月 30 日召开 第六届董事会第二十六次会议、第六届监事会第二十一次会议，于 2025 年 10 月 16 日召开 2025 年第二次临时股东大会，审议通过了《关于现金收购控股子公 司石药集团巨石生物制药有限公司部分少数股权暨关联交易的议案》，同意公司 以现金方式购买石药集团恩必普药业有限公司持有的石药集团巨石生物制药有 限公司（以下简称"巨石生物"）29%股权。公司本次交易取得巨石生物 29%股 权的交易价款为 110,000.00 万元。交易完成后，公司持有巨石生物的股权比例将 由 51%增加至 80%。具体内容详见公司在巨潮资讯网（http://www.cninfo.com.cn） 披露的相关公告。 一、交易进展情况 石药集团恩必普药业有限公司：出资额 1 ...

Core Insights - Newnow's performance has been under pressure since its transition to innovative drugs, resulting in its first quarterly loss since going public in 2019, with a net profit of -24.05 million yuan for the first three quarters of this year, a year-on-year decline of 117.26% [1][2] Financial Performance - The sales expenses for Newnow increased by 87.12% to 202 million yuan, primarily due to increased marketing investments in the biopharmaceutical sector [2] - Research and development expenses rose by 49.56% to 683 million yuan, driven by Giant Stone Biotech's increased investment in R&D [2] - Newnow's net cash flow from operating activities was -175 million yuan for the first three quarters [4] Strategic Moves - Newnow is planning to further acquire a 29% stake in Giant Stone Biotech for 1.1 billion yuan, increasing its ownership from 51% to 80% [2] - The company aims to list on the Hong Kong Stock Exchange to enhance its global strategy and improve its capital operation platform [4] Market Performance - Newnow's stock price experienced significant volatility, with a cumulative increase of 134.65% from January 2 to June 6, followed by a decline of 47.89% from June 9 to November 5 [5] - As of November 5, Newnow's stock closed at 32.6 yuan per share, with a total market capitalization of 45.79 billion yuan [6] Management Issues - The former chairman of Newnow, Pan Weidong, was penalized for insider trading, leading to his resignation [7] - A planned acquisition of Shiyao Baike was ultimately terminated in April, indicating challenges in the company's strategic initiatives [8]

Core Insights - The company Xinnowei reported that as of October 31, 2025, the number of shareholders in its consolidated ordinary accounts and margin trading credit accounts is expected to reach 21,834 [2] Company Summary - The company is actively engaging with investors through interactive platforms to provide updates on shareholder numbers [2] - The projected increase in shareholder numbers indicates potential growth in investor interest and participation in the company's financial activities [2]

Core Viewpoint - Since transitioning to innovative drugs, the company has faced continuous pressure on its performance, resulting in its first-ever quarterly loss since its listing in 2019 [1][3]. Financial Performance - For the first three quarters of the year, the company reported a net profit attributable to shareholders of -24.04 million yuan, a year-on-year decline of 117.26% [2][3]. - Revenue for the same period was 1.59 billion yuan, reflecting a year-on-year increase of 7.71% [2][3]. - Sales expenses surged by 87.12% to 202 million yuan, primarily due to increased marketing investments in the biopharmaceutical sector [3]. - R&D expenses rose by 49.56% to 683 million yuan, driven by significant investments in innovation following the acquisition of Giant Bio [3]. Strategic Initiatives - The company is planning to strengthen its control over Giant Bio by acquiring an additional 29% stake for 1.1 billion yuan, increasing its ownership from 51% to 80% [3]. - The transition to innovative drugs is seen as a necessary move, despite its impact on short-term profits due to high R&D and marketing costs [4]. Market Activity - The company is preparing for an IPO in Hong Kong to enhance its global strategy and improve its capital operations [6]. - The company's cash flow from operating activities for the first three quarters was -175 million yuan, indicating financial strain [6]. Stock Performance - The company's stock has experienced significant volatility, with a 134.65% increase in the first half of the year, followed by a decline of over 40% since June 9 [7]. - As of November 5, the stock price was 32.6 yuan per share, with a total market capitalization of 45.79 billion yuan [8]. Management Changes - The former chairman was penalized for insider trading, which has raised concerns about governance [9]. - Following the resignation of the former chairman, the company appointed a new chairman, Yao Bing [10].

Core Points - The China Securities Regulatory Commission (CSRC) imposed a fine of 5 million RMB on Pan Weidong, an executive director of CSPC Pharmaceutical Group, for insider trading [2] - Pan Weidong's insider trading involved purchasing shares of New Horizon (a subsidiary of CSPC) prior to a planned acquisition announcement [2] - The acquisition plan was announced on January 10, 2024, while the stock purchases occurred between December 8 and December 20, 2023, totaling nearly 100 million RMB [2] - The stock purchases did not yield profits, as the current stock price of New Horizon is below the purchase price [2] - CSPC stated that the incident is not expected to negatively impact its overall business operations [4] Regulatory Actions - Pan Weidong contested the allegations, claiming that his actions were part of his official duties and that he did not evade the investigation [3] - The CSRC's administrative penalty was publicly announced on October 16, 2025, with CSPC disclosing the matter shortly after [3] - Other individuals involved in the case, including former executives of New Horizon and CSPC, received penalties for their trading activities, with some gaining profits from their transactions [5] Market Reaction - Following the announcement of the penalties, both CSPC and New Horizon experienced declines in their stock prices, with CSPC dropping 4.42% to 7.35 HKD per share and New Horizon falling 5.29% to 33.32 CNY per share [5]